Deep sequencing of gastric carcinoma reveals somatic mutations relevant to personalized medicine

Journal of Translational Medicine

Volumn 9, Issue 1, 2011, Pages

  Holbrook, Joanna D ^a,b   Parker, Joel S ^c   Gallagher, Kathleen T ^d   Halsey, Wendy S ^d   Hughes, Ashley M ^d   Weigman, Victor J ^c   Lebowitz, Peter F ^a   Kumar, Rakesh ^a  

^a Cancer Research   (United States)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c Expression Analysis Inc   (United States)

^d MDR   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CYCLE PROTEIN; DNA; MESSENGER RNA; SONIC HEDGEHOG PROTEIN; WNT PROTEIN; RNA; TUMOR PROTEIN;

AKT1 GENE; ARTICLE; AURKA GENE; BMP4 GENE; CCNE1 GENE; CDH1 GENE; CELL CYCLE; CHEMOSENSITIVITY; CLINICAL ARTICLE; CONTROLLED STUDY; DNA DAMAGE; DRUG TARGETING; EGFR GENE; EPITHELIAL MESENCHYMAL TRANSITION; ERBB2 GENE; GENE EXPRESSION PROFILING; GENE MUTATION; GPR78 GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; LPAR2 GENE; MET GENE; ONCOGENE; ONCOGENE K RAS; ONCOGENE MYC; PERSONALIZED MEDICINE; PIK3CA GENE; POLYMERASE CHAIN REACTION; PTCH1 GENE; RET GENE; S1PR2 GENE; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SMAD4 GENE; SOMATIC MUTATION; SSTR1 GENE; STOMACH ADENOCARCINOMA; TNFRSF6B GENE; TP53 GENE; ULK1 GENE; ZNF217 GENE; COPY NUMBER VARIATION; DNA SEQUENCE; ENZYMOLOGY; EPITHELIUM; GENE EXPRESSION REGULATION; GENETICS; GENOTYPE; HIGH THROUGHPUT SEQUENCING; METABOLISM; METHODOLOGY; MOLECULARLY TARGETED THERAPY; MUTATION; PATHOLOGY; PHENOTYPE; REPRODUCIBILITY; SIGNAL TRANSDUCTION; STOMACH TUMOR;

CELL CYCLE PROTEINS; DNA COPY NUMBER VARIATIONS; DNA, NEOPLASM; EPITHELIUM; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOTYPE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; INDIVIDUALIZED MEDICINE; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASM PROTEINS; PHENOTYPE; REPRODUCIBILITY OF RESULTS; RNA, NEOPLASM; SEQUENCE ANALYSIS, DNA; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; WNT PROTEINS;

EID: 79960583155     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-9-119     Document Type: Article

References (113)

1. Bertuccio P, Chatenoud L, Levi F, Praud D, Ferlay J, Negri E, Malvezzi M, La Vecchia C. Recent patterns in gastric cancer: a global overview. Int J Cancer 2009, 125:666-673. 10.1002/ijc.24290, 19382179.
2. Khosravi Shahi P, Diaz Munoz de la Espada VM, Garcia Alfonso P, Encina Garcia S, Izarzugaza Peron Y, Arranz Cozar JL, Hernandez Marin B, Perez Manga G. Management of gastric adenocarcinoma. Clin Transl Oncol 2007, 9:438-442. 10.1007/s12094-007-0082-8, 17652057.
3. Weinstein IB. Cancer. Addiction to oncogenes--the Achilles heal of cancer. Science 2002, 297:63-64. 10.1126/science.1073096, 12098689.
4. Weinstein IB, Joe A. Oncogene addiction. Cancer Res 2008, 68:3077-3080. discussion 3080, 10.1158/0008-5472.CAN-07-3293, 18451130.
5. Okines AF, Cunningham D. Trastuzumab in gastric cancer. Eur J Cancer 2010, 46:1949-1959. 10.1016/j.ejca.2010.05.003, 20542421.
6. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010, 376:687-697. 10.1016/S0140-6736(10)61121-X, 20728210.
7. Grabsch H, Sivakumar S, Gray S, Gabbert HE, Muller W. HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value - conclusions from 924 cases of two independent series. Cell Oncol 2010, 32:57-65.
8. Wainberg ZA, Anghel A, Desai AJ, Ayala R, Luo T, Safran B, Fejzo MS, Hecht JR, Slamon DJ, Finn RS. Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo. Clin Cancer Res 2010, 16:1509-1519. 10.1158/1078-0432.CCR-09-1112, 20179222.
9. Arkenau HT. Gastric cancer in the era of molecularly targeted agents: current drug development strategies. J Cancer Res Clin Oncol 2009, 135:855-866. 10.1007/s00432-009-0583-7, 19363621.
10. Ku GY, Ilson DH. Esophagogastric cancer: targeted agents. Cancer Treat Rev 2010, 36:235-248. 10.1016/j.ctrv.2009.12.009, 20122806.
11. Huang TJ, Wang JY, Lin SR, Lian ST, Hsieh JS. Overexpression of the c-met protooncogene in human gastric carcinoma--correlation to clinical features. Acta Oncol 2001, 40:638-643. 10.1080/028418601750444204, 11669338.
12. Kuniyasu H, Yasui W, Kitadai Y, Yokozaki H, Ito H, Tahara E. Frequent amplification of the c-met gene in scirrhous type stomach cancer. Biochem Biophys Res Commun 1992, 189:227-232. 10.1016/0006-291X(92)91548-5, 1333188.
13. Zhou D, Pan G, Zheng C, Zheng J, Yian L, Teng X. Expression of the RON receptor tyrosine kinase and its association with gastric carcinoma versus normal gastric tissues. BMC Cancer 2008, 8:353. 10.1186/1471-2407-8-353, 2629483, 19040718.
14. Buchanan SG, Hendle J, Lee PS, Smith CR, Bounaud PY, Jessen KA, Tang CM, Huser NH, Felce JD, Froning KJ, et al. SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo. Mol Cancer Ther 2009, 8:3181-3190. 10.1158/1535-7163.MCT-09-0477, 19934279.
15. Dai Y, Siemann DW. BMS-777607, a small-molecule met kinase inhibitor, suppresses hepatocyte growth factor-stimulated prostate cancer metastatic phenotype in vitro. Mol Cancer Ther 2010, 9:1554-1561. 10.1158/1535-7163.MCT-10-0359, 20515943.
16. Munshi N, Jeay S, Li Y, Chen CR, France DS, Ashwell MA, Hill J, Moussa MM, Leggett DS, Li CJ. ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. Mol Cancer Ther 2010, 9:1544-1553. 10.1158/1535-7163.MCT-09-1173, 20484018.
17. Pan BS, Chan GK, Chenard M, Chi A, Davis LJ, Deshmukh SV, Gibbs JB, Gil S, Hang G, Hatch H, et al. MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res 2010, 70:1524-1533. 10.1158/0008-5472.CAN-09-2541, 20145145.
18. Qian F, Engst S, Yamaguchi K, Yu P, Won KA, Mock L, Lou T, Tan J, Li C, Tam D, et al. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases. Cancer Res 2009, 69:8009-8016. 10.1158/0008-5472.CAN-08-4889, 19808973.
19. Smolen GA, Sordella R, Muir B, Mohapatra G, Barmettler A, Archibald H, Kim WJ, Okimoto RA, Bell DW, Sgroi DC, et al. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci USA 2006, 103:2316-2321. 10.1073/pnas.0508776103, 1413705, 16461907.
20. Wang MH, Padhye SS, Guin S, Ma Q, Zhou YQ. Potential therapeutics specific to c-MET/RON receptor tyrosine kinases for molecular targeting in cancer therapy. Acta Pharmacol Sin 2010, 31:1181-1188. 10.1038/aps.2010.106, 20694025.
21. Hattori Y, Itoh H, Uchino S, Hosokawa K, Ochiai A, Ino Y, Ishii H, Sakamoto H, Yamaguchi N, Yanagihara K, et al. Immunohistochemical detection of K-sam protein in stomach cancer. Clin Cancer Res 1996, 2:1373-1381.
22. Yashiro M, Shinto O, Nakamura K, Tendo M, Matsuoka T, Matsuzaki T, Kaizaki R, Miwa A, Hirakawa K. Synergistic antitumor effects of FGFR2 inhibitor with 5-fluorouracil on scirrhous gastric carcinoma. Int J Cancer 2010, 126:1004-1016.
23. Liu ZM, Liu LN, Li M, Zhang QP, Cheng SH, Lu S. Mutation detection of KRAS by high-resolution melting analysis in Chinese with gastric cancer. Oncol Rep 2009, 22:515-520.
24. Mita H, Toyota M, Aoki F, Akashi H, Maruyama R, Sasaki Y, Suzuki H, Idogawa M, Kashima L, Yanagihara K, et al. A novel method, digital genome scanning detects KRAS gene amplification in gastric cancers: involvement of overexpressed wild-type KRAS in downstream signaling and cancer cell growth. BMC Cancer 2009, 9:198. 10.1186/1471-2407-9-198, 2717977, 19545448.
25. Greshock J, Bachman KE, Degenhardt YY, Jing J, Wen YH, Eastman S, McNeil E, Moy C, Wegrzyn R, Auger K, et al. Molecular target class is predictive of in vitro response profile. Cancer Res 2010, 70:3677-3686. 10.1158/0008-5472.CAN-09-3788, 20406975.
26. Yoon YK, Kim HP, Han SW, Hur HS, Oh do Y, Im SA, Bang YJ, Kim TY. Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells. Mol Cancer Ther 2009, 8:2526-2536. 10.1158/1535-7163.MCT-09-0300, 19755509.
27. Lee JW, Soung YH, Kim SY, Lee HW, Park WS, Nam SW, Kim SH, Lee JY, Yoo NJ, Lee SH. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene 2005, 24:1477-1480. 10.1038/sj.onc.1208304, 15608678.
28. Oki E, Baba H, Tokunaga E, Nakamura T, Ueda N, Futatsugi M, Mashino K, Yamamoto M, Ikebe M, Kakeji Y, Maehara Y. Akt phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancer. Int J Cancer 2005, 117:376-380. 10.1002/ijc.21170, 15900596.
29. Velho S, Oliveira C, Ferreira A, Ferreira AC, Suriano G, Schwartz S, Duval A, Carneiro F, Machado JC, Hamelin R, Seruca R. The prevalence of PIK3CA mutations in gastric and colon cancer. Eur J Cancer 2005, 41:1649-1654. 10.1016/j.ejca.2005.04.022, 15994075.
30. Yu G, Wang J, Chen Y, Wang X, Pan J, Li G, Jia Z, Li Q, Yao JC, Xie K. Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of chinese patients with gastric cancer. Clin Cancer Res 2009, 15:1821-1829. 10.1158/1078-0432.CCR-08-2138, 19223493.
31. Cejka D, Preusser M, Fuereder T, Sieghart W, Werzowa J, Strommer S, Wacheck V. mTOR inhibition sensitizes gastric cancer to alkylating chemotherapy in vivo. Anticancer Res 2008, 28:3801-3808.
32. Cejka D, Preusser M, Woehrer A, Sieghart W, Strommer S, Werzowa J, Fuereder T, Wacheck V. Everolimus (RAD001) and anti-angiogenic cyclophosphamide show long-term control of gastric cancer growth in vivo. Cancer Biol Ther 2008, 7:1377-1385. 10.4161/cbt.7.9.6416, 18708754.
33. Doi T, Muro K, Boku N, Yamada Y, Nishina T, Takiuchi H, Komatsu Y, Hamamoto Y, Ohno N, Fujita Y, et al. Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer. J Clin Oncol 2010, 28:1904-1910. 10.1200/JCO.2009.26.2923, 20231677.
34. Fuereder T, Jaeger-Lansky A, Hoeflmayer D, Preusser M, Strommer S, Cejka D, Koehrer S, Crevenna R, Wacheck V. mTOR inhibition by everolimus counteracts VEGF induction by sunitinib and improves anti-tumor activity against gastric cancer in vivo. Cancer Lett 2010, 296:249-256. 10.1016/j.canlet.2010.04.015, 20471160.
35. Dar AA, Zaika A, Piazuelo MB, Correa P, Koyama T, Belkhiri A, Washington K, Castells A, Pera M, El-Rifai W. Frequent overexpression of Aurora Kinase A in upper gastrointestinal adenocarcinomas correlates with potent antiapoptotic functions. Cancer 2008, 112:1688-1698. 10.1002/cncr.23371, 18311783.
36. Kamada K, Yamada Y, Hirao T, Fujimoto H, Takahama Y, Ueno M, Takayama T, Naito A, Hirao S, Nakajima Y. Amplification/overexpression of Aurora-A in human gastric carcinoma: potential role in differentiated type gastric carcinogenesis. Oncol Rep 2004, 12:593-599.
37. Traynor AM, Hewitt M, Liu G, Flaherty KT, Clark J, Freedman SJ, Scott BB, Leighton AM, Watson PA, Zhao B, et al. Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors. Cancer Chemother Pharmacol 2010,
38. Blanke CD. Biomarkers in GIST: partly ready for prime-time use. Clin Cancer Res 2009, 15:5603-5605. 10.1158/1078-0432.CCR-09-1563, 19737947.
39. Marrari A, Trent JC, George S. Personalized cancer therapy for gastrointestinal stromal tumor: synergizing tumor genotyping with imatinib plasma levels. Curr Opin Oncol 2010, 22:336-341. 10.1097/CCO.0b013e32833a6b8e, 20489620.
40. Papaetis GS, Syrigos KN. Targeted therapy for gastrointestinal stromal tumors: current status and future perspectives. Cancer Metastasis Rev 2010, 29:151-170. 10.1007/s10555-010-9206-7, 20112054.
41. Zang ZJ, Ong CK, Cutcutache I, Yu W, Zhang SL, Huang D, Ler LD, Dykema K, Gan A, Tao J, et al. Genetic and structural variation in the gastric cancer kinome revealed through targeted deep sequencing. Cancer Res 2011, 71:29-39. 10.1158/0008-5472.CAN-10-1749, 21097718.
42. Liu ET. Functional genomics of cancer. Curr Opin Genet Dev 2008, 18:251-256. 10.1016/j.gde.2008.07.014, 18691651.
43. Wooster R, Bachman KE. Catalogue, cause, complexity and cure; the many uses of cancer genome sequence. Curr Opin Genet Dev 2010, 20:336-341. 10.1016/j.gde.2010.03.007, 20382522.
44. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 2009, 25:1754-1760. 10.1093/bioinformatics/btp324, 2705234, 19451168.
45. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin R. The Sequence Alignment/Map format and SAMtools. Bioinformatics 2009, 25:2078-2079. 10.1093/bioinformatics/btp352, 2723002, 19505943.
46. Buffart TE, van Grieken NC, Tijssen M, Coffa J, Ylstra B, Grabsch HI, van de Velde CJ, Carvalho B, Meijer GA. High resolution analysis of DNA copy-number aberrations of chromosomes 8, 13, and 20 in gastric cancers. Virchows Arch 2009, 455:213-223. 10.1007/s00428-009-0814-y, 2744787, 19697059.
47. Junnila S, Kokkola A, Karjalainen-Lindsberg ML, Puolakkainen P, Monni O. Genome-wide gene copy number and expression analysis of primary gastric tumors and gastric cancer cell lines. BMC Cancer 2010, 10:73. 10.1186/1471-2407-10-73, 2837868, 20187983.
48. Ng PC, Henikoff S. SIFT: Predicting amino acid changes that affect protein function. Nucleic Acids Res 2003, 31:3812-3814. 10.1093/nar/gkg509, 168916, 12824425.
49. Medlin MD, Staus DP, Dubash AD, Taylor JM, Mack CP. Sphingosine 1-phosphate receptor 2 signals through leukemia-associated RhoGEF (LARG), to promote smooth muscle cell differentiation. Arterioscler Thromb Vasc Biol 2010, 30:1779-1786. 10.1161/ATVBAHA.110.209395, 20702813.
50. Bamford S, Dawson E, Forbes S, Clements J, Pettett R, Dogan A, Flanagan A, Teague J, Futreal PA, Stratton MR, Wooster R. The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer 2004, 91:355-358. 2409828, 15188009.
51. Hingorani SR, Wang L, Multani AS, Combs C, Deramaudt TB, Hruban RH, Rustgi AK, Chang S, Tuveson DA. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 2005, 7:469-483. 10.1016/j.ccr.2005.04.023, 15894267.
52. Costanzo-Garvey DL, Pfluger PT, Dougherty MK, Stock JL, Boehm M, Chaika O, Fernandez MR, Fisher K, Kortum RL, Hong EG, et al. KSR2 is an essential regulator of AMP kinase, energy expenditure, and insulin sensitivity. Cell Metab 2009, 10:366-378. 10.1016/j.cmet.2009.09.010, 2773684, 19883615.
53. Dougherty MK, Ritt DA, Zhou M, Specht SI, Monson DM, Veenstra TD, Morrison DK. KSR2 is a calcineurin substrate that promotes ERK cascade activation in response to calcium signals. Mol Cell 2009, 34:652-662. 10.1016/j.molcel.2009.06.001, 2737517, 19560418.
54. Chan EY, Longatti A, McKnight NC, Tooze SA. Kinase-inactivated ULK proteins inhibit autophagy via their conserved C-terminal domains using an Atg13-independent mechanism. Mol Cell Biol 2009, 29:157-171. 10.1128/MCB.01082-08, 2612494, 18936157.
55. Wu WK, Cho CH, Lee CW, Wu YC, Yu L, Li ZJ, Wong CC, Li HT, Zhang L, Ren SX, et al. Macroautophagy and ERK phosphorylation counteract the antiproliferative effect of proteasome inhibitor in gastric cancer cells. Autophagy 2010, 6:228-238. 10.4161/auto.6.2.11042, 20087064.
56. Di Nicolantonio F, Arena S, Tabernero J, Grosso S, Molinari F, Macarulla T, Russo M, Cancelliere C, Zecchin D, Mazzucchelli L, et al. Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J Clin Invest 2010, 120:2858-2866. 10.1172/JCI37539, 2912177, 20664172.
57. Li VS, Wong CW, Chan TL, Chan AS, Zhao W, Chu KM, So S, Chen X, Yuen ST, Leung SY. Mutations of PIK3CA in gastric adenocarcinoma. BMC Cancer 2005, 5:29. 10.1186/1471-2407-5-29, 1079799, 15784156.
58. Chaussade C, Cho K, Mawson C, Rewcastle GW, Shepherd PR. Functional differences between two classes of oncogenic mutation in the PIK3CA gene. Biochem Biophys Res Commun 2009, 381:577-581. 10.1016/j.bbrc.2009.02.081, 19233141.
59. Soung YH, Lee JW, Nam SW, Lee JY, Yoo NJ, Lee SH. Mutational analysis of AKT1, AKT2 and AKT3 genes in common human carcinomas. Oncology 2006, 70:285-289. 10.1159/000096289, 17047397.
60. Katoh M. Genetic alterations of FGF receptors: an emerging field in clinical cancer diagnostics and therapeutics. Expert Rev Anticancer Ther 2010, 10:1375-1379. 10.1586/era.10.128, 20836672.
61. Turner N, Pearson A, Sharpe R, Lambros M, Geyer F, Lopez-Garcia MA, Natrajan R, Marchio C, Iorns E, Mackay A, et al. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res 2010, 70:2085-2094. 10.1158/0008-5472.CAN-09-3746, 2832818, 20179196.
62. Bertotti A, Bracco C, Girolami F, Torti D, Gastaldi S, Galimi F, Medico E, Elvin P, Comoglio PM, Trusolino L. Inhibition of Src impairs the growth of met-addicted gastric tumors. Clin Cancer Res 2010, 16:3933-3943. 10.1158/1078-0432.CCR-10-0106, 20628031.
63. Okamoto W, Okamoto I, Yoshida T, Okamoto K, Takezawa K, Hatashita E, Yamada Y, Kuwata K, Arao T, Yanagihara K, et al. Identification of c-Src as a potential therapeutic target for gastric cancer and of MET activation as a cause of resistance to c-Src inhibition. Mol Cancer Ther 2010, 9:1188-1197. 10.1158/1535-7163.MCT-10-0002, 20406949.
64. Chang W, Ma L, Lin L, Gu L, Liu X, Cai H, Yu Y, Tan X, Zhai Y, Xu X, et al. Identification of novel hub genes associated with liver metastasis of gastric cancer. Int J Cancer 2009, 125:2844-2853. 10.1002/ijc.24699, 19569046.
65. Kouraklis G, Katsoulis IE, Theocharis S, Tsourouflis G, Xipolitas N, Glinavou A, Sioka C, Kostakis A. Does the expression of cyclin E, pRb, and p21 correlate with prognosis in gastric adenocarcinoma?. Dig Dis Sci 2009, 54:1015-1020. 10.1007/s10620-008-0464-y, 19058005.
66. Abate-Daga D, Garcia-Rodriguez L, Sumoy L, Fillat C. Cell cycle control pathways act as conditioning factors for TK/GCV sensitivity in pancreatic cancer cells. Biochim Biophys Acta 2010, 1803:1175-1185. 10.1016/j.bbamcr.2010.06.009, 20599444.
67. Phelps RA, Broadbent TJ, Stafforini DM, Jones DA. New perspectives on APC control of cell fate and proliferation in colorectal cancer. Cell Cycle 2009, 8:2549-2556. 10.4161/cc.8.16.9278, 19597346.
68. Ooi CH, Ivanova T, Wu J, Lee M, Tan IB, Tao J, Ward L, Koo JH, Gopalakrishnan V, Zhu Y, et al. Oncogenic pathway combinations predict clinical prognosis in gastric cancer. PLoS Genet 2009, 5:e1000676. 10.1371/journal.pgen.1000676, 2748685, 19798449.
69. Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, Joshi MB, Harpole D, Lancaster JM, Berchuck A, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006, 439:353-357. 10.1038/nature04296, 16273092.
70. Willert J, Epping M, Pollack JR, Brown PO, Nusse R. A transcriptional response to Wnt protein in human embryonic carcinoma cells. BMC Dev Biol 2002, 2:8. 10.1186/1471-213X-2-8, 117803, 12095419.
71. Chen W, Chen M, Barak LS. Development of small molecules targeting the Wnt pathway for the treatment of colon cancer: a high-throughput screening approach. Am J Physiol Gastrointest Liver Physiol 2010, 299:G293-300. 10.1152/ajpgi.00005.2010, 2928541, 20508156.
72. Ewan K, Pajak B, Stubbs M, Todd H, Barbeau O, Quevedo C, Botfield H, Young R, Ruddle R, Samuel L, et al. A useful approach to identify novel small-molecule inhibitors of Wnt-dependent transcription. Cancer Res 2010, 70:5963-5973. 10.1158/0008-5472.CAN-10-1028, 2912498, 20610623.
73. Huang SM, Mishina YM, Liu S, Cheung A, Stegmeier F, Michaud GA, Charlat O, Wiellette E, Zhang Y, Wiessner S, et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 2009, 461:614-620. 10.1038/nature08356, 19759537.
74. Katoh Y, Katoh M. Hedgehog target genes: mechanisms of carcinogenesis induced by aberrant hedgehog signaling activation. Curr Mol Med 2009, 9:873-886. 10.2174/156652409789105570, 19860666.
75. Wicking C, Shanley S, Smyth I, Gillies S, Negus K, Graham S, Suthers G, Haites N, Edwards M, Wainwright B, Chenevix-Trench G. Most germ-line mutations in the nevoid basal cell carcinoma syndrome lead to a premature termination of the PATCHED protein, and no genotype-phenotype correlations are evident. Am J Hum Genet 1997, 60:21-26. 1712561, 8981943.
76. Ma X, Chen K, Huang S, Zhang X, Adegboyega PA, Evers BM, Zhang H, Xie J. Frequent activation of the hedgehog pathway in advanced gastric adenocarcinomas. Carcinogenesis 2005, 26:1698-1705. 10.1093/carcin/bgi130, 15905200.
77. Dierks C. GDC-0449--targeting the hedgehog signaling pathway. Recent Results Cancer Res 2010, 184:235-238. 10.1007/978-3-642-01222-8_17, 20072843.
78. Amin SH, Tibes R, Kim JE, Hybarger CP. Hedgehog antagonist GDC-0449 is effective in the treatment of advanced basal cell carcinoma. Laryngoscope 2010,
79. Sabbah M, Emami S, Redeuilh G, Julien S, Prevost G, Zimber A, Ouelaa R, Bracke M, De Wever O, Gespach C. Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers. Drug Resist Updat 2008, 11:123-151. 10.1016/j.drup.2008.07.001, 18718806.
80. Katoh M. Epithelial-mesenchymal transition in gastric cancer (Review). Int J Oncol 2005, 27:1677-1683.
81. Pohl M, Radacz Y, Pawlik N, Schoeneck A, Baldus SE, Munding J, Schmiegel W, Schwarte-Waldhoff I, Reinacher-Schick A. SMAD4 mediates mesenchymal-epithelial reversion in SW480 colon carcinoma cells. Anticancer Res 2010, 30:2603-2613.
82. Linger RJ, Kruk PA. BRCA1 16 years later: risk-associated BRCA1 mutations and their functional implications. FEBS J 2010, 277:3086-3096. 10.1111/j.1742-4658.2010.07735.x, 20608970.
83. Shim HJ, Yun JY, Hwang JE, Bae WK, Cho SH, Lee JH, Kim HN, Shin MH, Kweon SS, Kim HJ, Chung IJ. BRCA1 and XRCC1 polymorphisms associated with survival in advanced gastric cancer treated with taxane and cisplatin. Cancer Sci 2010, 101:1247-1254. 10.1111/j.1349-7006.2010.01514.x, 20331623.
84. Wang L, Wei J, Qian X, Yin H, Zhao Y, Yu L, Wang T, Liu B. ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel. BMC Cancer 2008, 8:97. 10.1186/1471-2407-8-97, 2394535, 18402708.
85. Yashiro M, Inoue T, Nishioka N, Matsuoka T, Boland CR, Hirakawa K. Allelic imbalance at p53 and microsatellite instability are predictive markers for resistance to chemotherapy in gastric carcinoma. Ann Surg Oncol 2009, 16:2926-2935. 10.1245/s10434-009-0590-6, 2865194, 19597886.
86. Murr R, Vaissiere T, Sawan C, Shukla V, Herceg Z. Orchestration of chromatin-based processes: mind the TRRAP. Oncogene 2007, 26:5358-5372. 10.1038/sj.onc.1210605, 17694078.
87. Calonge TM, Eshaghi M, Liu J, Ronai Z, O'Connell MJ. Transformation/transcription domain-associated protein (TRRAP)-mediated regulation of Wee1. Genetics 2010, 185:81-93. 10.1534/genetics.110.114769, 2870978, 20194963.
88. Campas-Moya C. Romidepsin for the treatment of cutaneous T-cell lymphoma. Drugs Today (Barc) 2009, 45:787-795.
89. Copeland A, Buglio D, Younes A. Histone deacetylase inhibitors in lymphoma. Curr Opin Oncol 22:431-436.
90. Janetka JW, Ashwell S. Checkpoint kinase inhibitors: a review of the patent literature. Expert Opin Ther Pat 2009, 19:165-197. 10.1517/13543770802653622, 19441917.
91. Kavanaugh SM, White LA, Kolesar JM. Vorinostat: A novel therapy for the treatment of cutaneous T-cell lymphoma. Am J Health Syst Pharm 2010, 67:793-797. 10.2146/ajhp090247, 20479100.
92. Morgan MA, Parsels LA, Zhao L, Parsels JD, Davis MA, Hassan MC, Arumugarajah S, Hylander-Gans L, Morosini D, Simeone DM, et al. Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair. Cancer Res 2010, 70:4972-4981. 10.1158/0008-5472.CAN-09-3573, 2889008, 20501833.
93. Abramowicz MJ, Duprez L, Parma J, Vassart G, Heinrichs C. Familial congenital hypothyroidism due to inactivating mutation of the thyrotropin receptor causing profound hypoplasia of the thyroid gland. J Clin Invest 1997, 99:3018-3024. 10.1172/JCI119497, 508154, 9185526.
94. Garcia-Jimenez C, Santisteban P. TSH signalling and cancer. Arq Bras Endocrinol Metabol 2007, 51:654-671. 10.1590/S0004-27302007000500003, 17891229.
95. van Dekken H, Geelen E, Dinjens WN, Wijnhoven BP, Tilanus HW, Tanke HJ, Rosenberg C. Comparative genomic hybridization of cancer of the gastroesophageal junction: deletion of 14Q31-32. 1 discriminates between esophageal (Barrett's) and gastric cardia adenocarcinomas. Cancer Res 1999, 59:748-752.
96. Hanauer DA, Rhodes DR, Sinha-Kumar C, Chinnaiyan AM. Bioinformatics approaches in the study of cancer. Curr Mol Med 2007, 7:133-141. 10.2174/156652407779940431, 17311538.
97. Henkhaus RS, Gerner EW, Ignatenko NA. Kallikrein 6 is a mediator of K-RAS-dependent migration of colon carcinoma cells. Biol Chem 2008, 389:757-764. 10.1515/BC.2008.087, 18627290.
98. Nagahara H, Mimori K, Utsunomiya T, Barnard GF, Ohira M, Hirakawa K, Mori M. Clinicopathologic and biological significance of kallikrein 6 overexpression in human gastric cancer. Clin Cancer Res 2005, 11:6800-6806. 10.1158/1078-0432.CCR-05-0943, 16203767.
99. Lochhead PA, Wickman G, Mezna M, Olson MF. Activating ROCK1 somatic mutations in human cancer. Oncogene 2010, 29:2591-2598. 10.1038/onc.2010.3, 20140017.
100. Volk J, Parsonnet J. Epidemiology od Gastric Cancer and Helicobacter pylori. The Biology of Gastric Cancers 2009, Springer, Wang T, Fox J, Giraud A.
101. Compare D, Rocco A, Nardone G. Risk factors in gastric cancer. Eur Rev Med Pharmacol Sci 2010, 14:302-308.
102. Marshall BJ, McGechie DB, Rogers PA, Glancy RJ. Pyloric Campylobacter infection and gastroduodenal disease. Med J Aust 1985, 142:439-444.
103. Israel DA, Peek RM. The role of Helicobacter pylori virulence factors in rodent and primate models of disease. The Biology of Gastric Cancers 2009, 403-423. Springer, Wang T, Fox J, Giraud A.
104. Machado AM, Figueiredo C, Seruca R, Rasmussen LJ. Helicobacter pylori infection generates genetic instability in gastric cells. Biochim Biophys Acta 2010, 1806:58-65.
105. Von Hoff DD, Stephenson JJ, Rosen P, Loesch DM, Borad MJ, Anthony S, Jameson G, Brown S, Cantafio N, Richards DA, et al. Pilot Study Using Molecular Profiling of Patients' Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers. J Clin Oncol 2010,
106. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008, 455:1061-1068. 10.1038/nature07385, 2671642, 18772890.
107. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008, 321:1801-1806. 10.1126/science.1164368, 2848990, 18772397.
108. Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K, Koboldt DC, Fulton RS, Delehaunty KD, McGrath SD, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009, 361:1058-1066. 10.1056/NEJMoa0903840, 19657110.
109. Pleasance ED, Stephens PJ, O'Meara S, McBride DJ, Meynert A, Jones D, Lin ML, Beare D, Lau KW, Greenman C, et al. A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature 2010, 463:184-190. 10.1038/nature08629, 2880489, 20016488.
110. Shah SP, Morin RD, Khattra J, Prentice L, Pugh T, Burleigh A, Delaney A, Gelmon K, Guliany R, Senz J, et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 2009, 461:809-813. 10.1038/nature08489, 19812674.
111. Weir BA, Woo MS, Getz G, Perner S, Ding L, Beroukhim R, Lin WM, Province MA, Kraja A, Johnson LA, et al. Characterizing the cancer genome in lung adenocarcinoma. Nature 2007, 450:893-898. 10.1038/nature06358, 2538683, 17982442.
112. Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, Leary RJ, Shen D, Boca SM, Barber T, Ptak J, et al. The genomic landscapes of human breast and colorectal cancers. Science 2007, 318:1108-1113. 10.1126/science.1145720, 17932254.
113. Simon R. Clinical trial designs for evaluating the medical utility of prognostic and predictive biomarkers in oncology. Per Med 2010, 7:33-47. 10.2217/pme.09.49, 2851173, 20383292.